- See the press release here.
- See the product website here - the Oncomine DX Target Test.
- FDA Documentation under PMA #P160045.
- The the FDA 51-page Safety and Effectiveness review of Oncomine Dx Target Test, here.
- The 398-page FDA User Guide, here.
- The 6-page physician insert, here.
- The FDA's approval letter here, June 22, 5-page.
- See initial coverage at Genomeweb, here. Genomeweb notes that the test can run on as little as 10 ng of DNA.
- A subscription deep-dive article at Genomeweb followed, here.
- Coverage at MedCityNews, here.
- Coverage at WIRED, here.
- At FDA.gov, see the Drug/CDx page here, listing ONcomine Dx Target Test as associated with drug NDAs on four drugs, Tafinlar, Mekinist, Xalkor, Iressa (here).
Still in the FDA pipeline are tumor oncogene panel tests developed by Illumina and Foundation Medicine.
The cited Thermo Fisher press release is quoted below the break. The product will be rolled out at a number of major US reference labs beginning in July.
CARLSBAD, Calif., June 22, 2017 /PRNewswire/
The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific for the first next-generation sequencing (NGS)-based test that simultaneously screens tumor samples for biomarkers associated with three FDA-approved therapies for non-small cell lung cancer (NSCLC). Lung cancer is the leading cause of cancer-related deaths in the U.S., with NSCLC accounting for 85 percent of all lung cancers.1
The Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC.
Following FDA approval, results from analysis of three of these genes can now be used to identify patients who may be eligible for treatment with one of the following: the combined therapy of Tafinlar® and Mekinist®, XALKORI®, or IRESSA®. With this test, physicians can now match patients to these therapies in days instead of several weeks, which it often takes when screening samples one biomarker at a time.
FDA approves the Oncomine Dx Target Test, the first companion diagnostic of its kind that simultaneously screens tumor samples for biomarkers associated with three approved targeted therapies. The test is designed to help oncologists expedite selection of a treatment plan for their patients in days instead of weeks.
FDA approves the Oncomine Dx Target Test, the first companion diagnostic of its kind that simultaneously screens tumor samples for biomarkers associated with three approved targeted therapies. The test is designed to help oncologists expedite selection of a treatment plan for their patients in days instead of weeks.
"For people battling non-small cell lung cancer, time is critical and days matter," said Joydeep Goswami, president of clinical next-generation sequencing and oncology at Thermo Fisher. "The Oncomine Dx Target Test rapidly guides oncologists toward the right targeted therapy, with the goal of improving patient outcomes and the cost-efficiency of treatments."
LabCorp's Diagnostics and Covance Businesses, NeoGenomics Laboratories, and Cancer Genetics, Inc., are among the first laboratories that will offer the Oncomine Dx Target Test as a service to oncologists. All tests will be run on Thermo Fisher's Ion PGM Dx System, which received FDA 510(k) clearance in parallel for use on formalin-fixed, paraffin-embedded (FFPE) tissue samples.
"This first iteration of the test is just the beginning since the diagnostic claims of the Oncomine Dx Target Test may be expanded in the future based on the existing panel," Goswami added. "Thermo Fisher has entered into discussions with several pharmaceutical companies looking to use the panel for FDA-approved targeted therapy applications beyond lung cancer. Expanding the range of clinically actionable information is part of the company's goal to help our customers advance precision medicine."
Thermo Fisher developed the Oncomine Dx Target Test in collaboration with Novartis and Pfizer. It is based on Thermo Fisher's Ion AmpliSeq technology, which enables screening of tumor samples for multiple genetic markers with 10 nanograms of nucleic acid. Returning results using such a small amount of FFPE material is a critical advantage of the test since samples from patients with NSCLC are often limited in quantity.
More information about the Oncomine Dx Target Test is available at www.thermofisher.com/oncomine-dxtarget.
Tafinlar® and Mekinist® are registered trademarks of Novartis; XALKORI® is a registered trademark of Pfizer; and IRESSA® is a registered trademark of AstraZeneca.
1. Non–Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship; Julian R. Molina, MD, PhD, Ping Yang, MD, PhD, Stephen D. Cassivi, MD, Steven E. Schild, MD, and Alex A. Adjei, MD, PhD
